Ad5-nCoV vaccine safe and effective against symptomatic, severe COVID-19, trials shows

Single dose of Ad5-nCoV (Convidecia), a COVID-19 vaccine developed in China, is 57.5% effective against symptoms of COVID-19 and 91.7% effective against severe COVID-19 disease onset 28 days after vaccination, according to a randomized phase 3 Censored trial published in scalpel. The report indicates that Ad5-nCoV is safe, with no serious vaccine-related adverse events or … Read more